Free Trial
→ OpenAI’s new $300 billion deal (From Porter & Company) (Ad)tc pixel

ImmuPharma (LON:IMM) Stock Price Up 30.2% - What's Next?

Written by MarketBeat
September 16, 2025
ImmuPharma logo with Medical background

Key Points

  • ImmuPharma's share price surged by 30.2% during mid-day trading, reaching a high of GBX 19.35 ($0.26), following a significant increase in trading volume.
  • The company reported a negative earnings per share of GBX (0.38) for the quarter, with analysts predicting an even more significant loss for the current fiscal year.
  • ImmuPharma is a biopharmaceutical firm focusing on peptide-based therapeutics, with its lead program being P140 (Lupuzor™), aimed at treating autoimmune diseases such as Lupus.
  • Five stocks we like better than ImmuPharma.

ImmuPharma plc (LON:IMM - Get Free Report)'s share price rose 30.2% during mid-day trading on Monday . The company traded as high as GBX 19.35 ($0.26) and last traded at GBX 18.20 ($0.25). Approximately 42,196,645 shares traded hands during trading, an increase of 407% from the average daily volume of 8,315,265 shares. The stock had previously closed at GBX 13.98 ($0.19).

ImmuPharma Stock Up 25.3%

The company has a market capitalization of £87.51 million, a P/E ratio of -1,967.53 and a beta of 1.53. The firm has a 50-day moving average price of GBX 3.12 and a two-hundred day moving average price of GBX 2.91.

ImmuPharma (LON:IMM - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. On average, analysts predict that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

ImmuPharma Company Profile

(Get Free Report)

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in ImmuPharma Right Now?

Before you consider ImmuPharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmuPharma wasn't on the list.

While ImmuPharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover
The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report
Like this article? Share it with a colleague.